loader2
Partner With Us NRI

Company details

385.75
400.95
250.00
692.00
6M Return -28.13%
1Y Return 47.31%
Mkt Cap.(Cr) 569.54
Volume 2,423
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 2,423

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 69.94 Cr FV: 5.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 30,916.98 -44,588.21
LAST 3M 83,461.15 -41,404.02
LAST 6M 143,250.83 -190,265.70
LAST 12M 204,102.65 -163,801.53

Information

  • About Company
  • Company Info
  • Listing Info
13.98
74.99%
66.5211
66.39%
53.83%
Description
  • Promoted by Kantilal Shah and the Gujarat Industrial Investment Corporation, Gujarat Themis Biosyn (GTBL) was incorporated in Dec.`81 as a public limited company. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990. However, problems relating to purity levels, yield and imports put the company in the red and it became a BIFR case in 1990. Subsequently, it was taken over by a group consisting of Lyka Labs, Themis Chemicals, Kopran and Cadila. Also, Yuhan Corporation, South Korea, brought in technology and finance for running GTBL. During 1995-96 the paid-up share capital increased from Rs 11.25 crores to Rs 11.60 crores after allotment of 350,000 Equity shares of Rs 10 each at a premium of Rs 20 per share to the financial institutions by way of conversion of fund interst term loan. During the year installed capacity of rifamysin-S was increased to 90 mtpa and expansion of rifampicin was achieved to the maximum capacity of 120 mtpa. It also commenced operations of its new pharmaceutical division and launched a wide range of anti-tuberculosis products and other antibiotics. The company is constantly identifying new areas for diversification and also capacity expansion of exisiting product in order to further reduction in cost of production and increase in turnover.

Read More

No Data Found

AGM Date (Month) : Sep
Face Value Equity Shares : 5
Market Lot Equity Shares : 1
BSE Code : 506879
NSE Code : GUJTHEMIS
Book Closure Date (Month) : Sep
BSE Group : X
ISIN : INE942C01029

ICICIdirect Gujarat Themis Biosyn Ltd FAQ

You can buy Gujarat Themis Biosyn Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Gujarat Themis Biosyn Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 16, 2022 11:38 AM the closing price of Gujarat Themis Biosyn Ltd was ₹ 392.00.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 16, 2022 11:38 AM, the market cap of Gujarat Themis Biosyn Ltd stood at ₹ 569.54.
The latest PE ratio of Gujarat Themis Biosyn Ltd as of May 16, 2022 11:38 AM is 13.98
The latest PB ratio of Gujarat Themis Biosyn Ltd as of May 16, 2022 11:38 AM is 0.17
The 52-week high of Gujarat Themis Biosyn Ltd is ₹ 692.00 while the 52-week low is ₹ 250.00 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE